[Effectiveness and safety of rituximab for children with autoimmune diseases of the nervous system].

医学 美罗华 视神经脊髓炎 重症肌无力 自身免疫性脑炎 多发性硬化 内科学 儿科 免疫学 抗体 淋巴瘤 自身抗体
作者
Zhifang Fu,Xunxia Bao,Yiling Wu,Jiaojie Zhou,Yimin Zhang,Yi Zhang,Taoyun Ji,Y Chen
出处
期刊:PubMed 卷期号:55 (9): 689-694 被引量:3
标识
DOI:10.3760/cma.j.issn.0578-1310.2017.09.013
摘要

Objective: To assess the effectiveness and safety of rituximab in Chinese children with autoimmune diseases of the nervous system. Method: An ambispective cohort study enrolled patients with refractory and(or) relapse autoimmune diseases of nervous system from June 2010 to June 2016 in Peking University First Hospital.These patients failed to respond to steroids and(or)intravenous immunoglobulin (IVIG) were treated with rituximab and seen for follow-up visits once every 3 months.The effectiveness was assessed by modified Rankin scale (mRs) and the annualized relapse rate.B cell was repeatedly counted after the treatment.Side effects attributed to rituximab were recorded.Paired rank test and chi-square test were used to compare the mRs score and the recurrence rate (time/year) before and after the treatment. Result: A total of 38 patients (15 males and 23 females) with mean age of (6±4) years were treated with rituximab.Among those patients, 4 cases were in multiple sclerosis, 5 in neuromyelitis optica, 6 in opsoclonus myoclonus syndrome, 9 in myasthenia gravis, and 14 in autoimmune encephalitis and other nervous system autoimmune diseases.The course of the disease before rituximab treatment was from two months to 7.25 years, with the average of (21±19) months.The patients had been followed up for 2-52 months. The mRs score and recurrence rate of 38 patients before receiving rituximab was 3 points (3, 4) and 2.56 (1.80, 4.75) times per year, respectively, while patients after receiving rituximab were mRs score of 0 (0, 2) and had a recurrence rate of 0 (0, 0.17) per year.There was statistical difference before and after treatment (Z=-4.51 and -4.71, P<0.01). Rituximab had a definite benefit in 23 patients, probable benefit in 2 patients, possible benefit in 3 patients, no benefit in one patient, and the disease worsened in 2 patients.Therefore the total effective rate was 74%, except for 6 undetermined cases because of the short follow-up time, and one patient withdrew from the study due to allergic reaction.During the follow-up, only one patient with severe allergy gave up the rituximab treatment. And only one patient was found severe infection with Pneumocystis carinii pneumonia. Conclusion: Rituximab is an effective and safe treatment strategy for patients with refractory and relapse autoimmune diseases of CNS, especially in neuromyelitis optica and myasthenia gravis.The adverse events including infection and allergy during infusion are not common.目的: 评价利妥昔单抗在儿童神经系统自身免疫性疾病治疗中的效果及安全性。 方法: 采用双向性队列研究,对2010年6月至2016年6月于北京大学第一医院儿科诊断为神经系统自身免疫性疾病,经糖皮质激素或免疫球蛋白治疗无效或复发的住院患儿给予利妥昔单抗治疗,并每3个月随访1次,应用改良Rankin量表及年复发率进行疗效评价;行B细胞数值监测;观察药物的不良反应。采用配对秩和检验对每种疾病治疗前后应用改良Rankin量表评分及复发率(次/年)进行比较。 结果: 应用利妥昔单抗治疗的患儿共38例,其中男15例、女23例,平均年龄(6±4)岁,其中多发性硬化4例,视神经脊髓炎5例,眼球阵挛肌阵挛综合征6例,重症肌无力9例,免疫性脑炎及其他神经系统免疫性疾病14例。患儿病程2~87个月,平均(21±19)个月,随访时间2~52个月。38例患儿使用利妥昔单抗前改良Rankin量表评分3(3,4)分,年复发率2.56(1.8,4.75)次/年,使用利妥昔单抗后改良Rankin量表评分0(0,2)分,年复发率0(0,0.17)次/年,二者治疗前后差异均有统计学意义(Z=-4.51、-4.71,P均<0.01)。38例患儿中控制23例,显效2例,有效3例,无效1例,加重2例,因随访时间短不能确定疗效6例,因过敏反应退出治疗1例,总有效率74%。出现严重的肺部卡氏肺囊虫感染1例。 结论: 利妥昔单抗治疗儿童难治性、复发性神经系统自身免疫性疾病尤其是视神经脊髓炎和重症肌无力安全性好,常见不良反应为过敏和感染。.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Q0应助麟儿采纳,获得10
2秒前
3秒前
yyc666发布了新的文献求助10
4秒前
崔罗石发布了新的文献求助10
5秒前
情怀应助HaohaoLi采纳,获得10
5秒前
燕尔蓝完成签到,获得积分10
5秒前
小水完成签到 ,获得积分10
6秒前
XYZ发布了新的文献求助10
7秒前
7秒前
8秒前
梅赛德斯完成签到,获得积分10
10秒前
11秒前
天天快乐应助CJY采纳,获得10
11秒前
独特的夜阑完成签到 ,获得积分10
12秒前
orixero应助lyzhou采纳,获得10
12秒前
小黄人发布了新的文献求助10
12秒前
13秒前
奥特曼完成签到,获得积分10
15秒前
16秒前
脑洞疼应助科研通管家采纳,获得30
16秒前
Lin应助科研通管家采纳,获得10
16秒前
堂风发布了新的文献求助10
17秒前
我是老大应助科研通管家采纳,获得10
17秒前
昏睡的蟠桃应助李思超采纳,获得204
17秒前
乐观小之应助科研通管家采纳,获得10
17秒前
17秒前
Jasper应助科研通管家采纳,获得10
17秒前
华仔应助科研通管家采纳,获得10
17秒前
wanci应助科研通管家采纳,获得10
17秒前
丘比特应助科研通管家采纳,获得10
17秒前
今后应助科研通管家采纳,获得10
17秒前
爆米花应助科研通管家采纳,获得10
17秒前
领导范儿应助科研通管家采纳,获得10
17秒前
FashionBoy应助科研通管家采纳,获得10
18秒前
18秒前
19秒前
蒋文辉发布了新的文献求助10
19秒前
木槿花难开完成签到,获得积分10
20秒前
HaohaoLi发布了新的文献求助10
22秒前
高分求助中
Mass producing individuality 600
Разработка метода ускоренного контроля качества электрохромных устройств 500
A Combined Chronic Toxicity and Carcinogenicity Study of ε-Polylysine in the Rat 400
How We Sold Our Future: The Failure to Fight Climate Change 200
Lab Dog: What Global Science Owes American Beagles 200
Governing Marine Living Resources in the Polar Regions 200
Bazaar to piazza. Islamic trade and Italian art, 1300–1600 200
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3824546
求助须知:如何正确求助?哪些是违规求助? 3366845
关于积分的说明 10443056
捐赠科研通 3086168
什么是DOI,文献DOI怎么找? 1697764
邀请新用户注册赠送积分活动 816478
科研通“疑难数据库(出版商)”最低求助积分说明 769719